Anadolu Psikiyatri Dergisi || ISSN: 1302-6631 || Volume 27; Number 1
https://doi.org/10.5281/zenodo.18400986

The Glutamate Hypothesis of Schizophrenia: Current Evidence and Implications for Precision Psychiatry

Authors: Izabela Majchrzak[1] ORCID: 0009-0009-0682-7184, **Martyna Lenartowicz**[1] ORCID: 0009-0008-3452-6090, **Kornella Zieleń**[1] ORCID: 0009- 0007-3440-909X, **Joanna Cygan**[5] ORCID: 0009-0000-5512-8261,**Sandra Moska**[2] ORCID: 0009-0004-5475-3216, **Anna Lemańska**[3] ORCID: 0009-0008-3207-1248, **Dagmara Kanar**[4] ORCID: 0009-0005-5577-5334, **Julia Klincewicz**[1] ORCID: 0009-0002-2135-0117, **Antonina Woźnicka**[1] ORCID: 0009-0001-3602-4819,

Authors Affiliation:

[1]University Clinical Hospital in Poznań, Poland

[2]Regional Hospital in Poznań, Poland

[3]Central Clinical Hospital, Uniwersity Clinical Center of the Medical University of Warsaw, Poland

[4]Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Faculty of Medicine, Poland

[5]Independent Public Health Care Facility of the Ministry of Interior and Administration in Katowice, Poland

Corresponding Author: Izabela Majchrzak

Abstract

The dopamine hypothesis of schizophrenia, dominant for over five decades, has limitations in explaining the full spectrum of symptoms, particularly cognitive deficits and treatment-resistant psychosis. The glutamate hypothesis has emerged as a complementary and increasingly supported framework for understanding schizophrenia pathophysiology. This review synthesizes current evidence regarding glutamatergic dysfunction in schizophrenia and its implications for precision psychiatry. We examine neurobiological mechanisms of N-methyl-D-aspartate (NMDA) receptor hypofunction, neuroimaging biomarkers including magnetic resonance spectroscopy and functional connectivity abnormalities, immunological evidence including anti-NMDA receptor antibodies, and pharmacological interventions targeting the glutamate system. We discuss how glutamatergic biomarkers may stratify patient populations, predict treatment response, and guide personalized therapeutic approaches. Emerging evidence suggests that glutamatergic dysfunction represents a convergence point for multiple pathophysiological pathways in schizophrenia, offering novel opportunities for biomarker-driven diagnosis and treatment selection. This comprehensive overview provides a foundation for implementing precision psychiatry approaches based on glutamatergic dysfunction in clinical settings.

1. INTRODUCTION

Schizophrenia remains one of the most severe and costly mental health disorders, affecting approximately 1% of the global population with profound impacts on cognitive, social, and occupational functioning. Despite decades of research and pharmacological development, the fundamental neurobiological mechanisms underlying schizophrenia remain incompletely understood. The dopamine hypothesis, proposed by Van Rossum in 1966 and refined through subsequent decades, has provided the theoretical foundation for antipsychotic drug development and has been instrumental in understanding psychotic symptoms.[2,3] However, this model has significant limitations: approximately one-third of patients show poor response to dopamine-blocking agents, cognitive symptoms remain largely unresponsive to current treatments, and many antipsychotics produce substantial adverse effects.[4,5]

The glutamate hypothesis of schizophrenia offers a complementary and increasingly evidence-supported framework for understanding disease pathophysiology. This hypothesis posits that hypofunction of the N-methyl-D-aspartate (NMDA) receptor, a subtype of ionotropic glutamate receptor crucial for excitatory neurotransmission, represents a core pathophysiological mechanism in schizophrenia.[6,7] The hypothesis emerged from clinical observations that NMDA receptor antagonists such as phencyclidine (PCP) and ketamine reliably induce schizophrenia-like positive, negative, and cognitive symptoms in healthy individuals and can exacerbate symptoms in patients with schizophrenia.

The transition toward understanding schizophrenia as a disorder of glutamatergic dysfunction has profound implications for therapeutics and clinical stratification. Unlike the relatively homogeneous dopaminergic model, glutamatergic pathophysiology encompasses multiple mechanistic pathways including NMDA receptor hypofunction, excitatory-inhibitory imbalance, abnormalities in glutamate-glutamine cycling, and potentially autoimmune mechanisms involving anti-NMDA receptor antibodies.[9,10] These mechanistic subtypes may represent distinct biological phenotypes within the schizophrenia spectrum, offering opportunities for precision medicine approaches that match treatment interventions to underlying biological mechanisms.

This comprehensive review synthesizes current evidence regarding the glutamate hypothesis of schizophrenia and articulates its implications for precision psychiatry. We examine: (1) the neurobiological basis of NMDA receptor hypofunction and excitatory-inhibitory imbalance; (2) in vivo neuroimaging biomarkers of glutamatergic dysfunction; (3) immunological evidence including anti-NMDA receptor antibodies; (4) relationships between glutamatergic abnormalities and symptom severity and treatment response; and (5) emerging pharmacological interventions and biomarker-guided therapeutic strategies.

2. Mechanisms of Glutamatergic Dysfunction in Schizophrenia

2.1 NMDA Receptor Hypofunction and the "Hypofunction Hypothesis"

The NMDA receptor is a ligand-gated ion channel that plays a crucial role in synaptic plasticity, learning, and memory through calcium-mediated signaling cascades. The receptor requires simultaneous binding of glutamate and a co-agonist (glycine or D-serine) at separate binding sites for channel opening and ion influx. The NMDA receptor subunit composition varies across brain regions and developmental stages, with NR1/NR2A and NR1/NR2B heteromers being the predominant configurations in adult cortex.

The NMDA receptor hypofunction hypothesis proposes that reduced NMDA receptor signaling, rather than elevated glutamate levels per se, constitutes the primary pathophysiological abnormality in schizophrenia. This hypothesis specifically draws from the observation that non-competitive NMDA receptor antagonists like ketamine and PCP induce a comprehensive symptom profile resembling schizophrenia, including positive symptoms, negative symptoms, cognitive deficits, and perceptual abnormalities.[15,16] Critically, the ketamine model not only produces symptoms but also induces neurophysiological and neuroimaging abnormalities remarkably similar to those observed in schizophrenia patients, providing strong support for the mechanistic relevance of NMDA hypofunction.

The specific consequences of NMDA receptor hypofunction have been extensively characterized in preclinical models. NMDA receptors on fast-spiking, parvalbumin-positive GABAergic interneurons are particularly important for their inhibitory function. When NMDA receptors on these interneurons are blocked or hypoactive, GABAergic interneuron firing is reduced, leading to disinhibition of downstream pyramidal neurons. This excitatory-inhibitory imbalance represents a fundamental mechanism by which NMDA hypofunction could generate psychotic and cognitive symptoms. The resulting pyramidal neuron hyperactivity may manifest as elevated glutamate release from these excitatory neurons, creating the paradoxical situation of clinical NMDA hypofunction coexisting with regional hyperglutamatergic states.

Postmortem studies have provided evidence for molecular abnormalities of NMDA receptors in schizophrenia. Decreased phosphorylation of NMDA receptor subunit NR1 at serine 897, a modification that regulates receptor trafficking and synaptic localization, has been documented in postmortem prefrontal cortex of schizophrenia patients. Additionally, altered expression of genes encoding NMDA receptor subunits and associated regulatory proteins has been reported.[23,24]

2.2 The Excitatory-Inhibitory Imbalance Model

The excitatory-inhibitory (E-I) imbalance framework provides a comprehensive model for understanding how NMDA receptor hypofunction translates into neuronal circuit dysfunction and behavioral symptoms.[25,26] In this model, the

normal balance between excitatory glutamatergic neurotransmission and inhibitory GABAergic neurotransmission is disrupted, leading to cascading effects on network function.

The preferential expression of NMDA receptors on GABAergic interneurons versus pyramidal neurons creates a critical vulnerability. NMDA receptors on parvalbumin-positive interneurons are particularly important for their local oscillatory activity and network coordination. When these NMDA receptors are hypoactive, GABAergic inhibition of pyramidal neurons is reduced, leading to pyramidal cell disinhibition and excessive glutamate release.

This disinhibition has been proposed to account for multiple aspects of schizophrenia pathophysiology. First, increased pyramidal neuron firing and glutamate release may contribute to positive symptoms through effects on mesolimbic dopamine systems. NMDA receptor knockout studies in cortical parvalbumin neurons demonstrate that this manipulation produces dopamine system abnormalities reminiscent of schizophrenia, including altered dopamine responses to psychotomimetic drugs.

Second, E-I imbalance may contribute to cognitive symptoms and working memory deficits through effects on prefrontal circuits. GABAergic interneurons are critical for maintaining the oscillatory activity patterns that support working memory. Reduced GABAergic inhibition from NMDA dysfunction could disrupt these essential oscillations.

Third, reduced GABAergic inhibition may manifest as increased background noise in neural circuits, reducing signal-to-noise ratio and hindering the organism's ability to distinguish relevant from irrelevant information. This phenomenon has been proposed to underlie perceptual abnormalities and positive symptoms of schizophrenia.

2.3 Glutamate-Glutamine Cycling and Metabolic Dysfunction

The glutamate-glutamine cycle represents an important metabolic relationship between glutamatergic neurons and glial cells. In this cycle, synaptically released glutamate is taken up by astrocytes via high-affinity glutamate transporters, converted to glutamine by glutamine synthetase, released back to neurons, and reconverted to glutamate by glutaminase. The ratio of glutamine to glutamate measured by magnetic resonance spectroscopy (MRS) is thought to reflect the efficiency of this cycling process and, by extension, the rate of glutamatergic neurotransmission.

Studies employing in vivo proton MRS have revealed abnormalities in glutamate-glutamine cycling in schizophrenia.[38,39] Elevated glutamine/glutamate ratios have been reported in cerebrospinal fluid and in some brain regions, suggesting altered neurotransmitter cycling.[40,41] In first-episode psychosis, a higher glutamine/glutamate ratio has been associated with reduced working memory performance, providing a potential link between metabolic dysfunction and cognitive symptoms.

The relationship between glutamine/glutamate ratios and functional outcomes appears complex and may depend on brain region and medication status. A landmark structural equation modeling study found that the glutamine/glutamate ratio served as an intermediate biomarker linking glutamatergic dysfunction to auditory mismatch negativity (MMN) and verbal working memory performance in schizophrenia. These findings suggest that glutamate-glutamine cycling abnormalities reflect meaningful variations in glutamatergic neurotransmission with clinical correlates.

3. Neuroimaging Evidence for Glutamatergic Dysfunction

3.1 Proton Magnetic Resonance Spectroscopy (1H-MRS) Studies

Proton magnetic resonance spectroscopy provides a non-invasive method to quantify regional brain levels of glutamate, glutamine, and GABA in vivo. This technique has substantially advanced our understanding of regional glutamatergic abnormalities in schizophrenia and has revealed important relationships between neurochemistry and clinical features.

3.1.1 Anterior Cingulate Cortex Glutamate in Relation to Treatment Response

The anterior cingulate cortex (ACC) has emerged as a particularly important region for understanding glutamatergic abnormalities in schizophrenia.[45,46] Converging evidence from multiple neuroimaging studies implicates elevated ACC glutamate levels as a biomarker for poor treatment response and treatment-resistant schizophrenia.

A landmark multicenter 1H-MRS study examining 103 first-episode psychosis patients found that baseline anterior cingulate glutamate levels predicted response to initial antipsychotic treatment. Patients with lower ACC glutamate levels at baseline were more likely to show clinical improvement with antipsychotic medication. Importantly, ACC glutamate levels appeared to normalize following 12 weeks of treatment in responders but remained elevated in non-responders, suggesting that ACC glutamate normalization may be mechanistically related to symptomatic improvement.

This finding has been replicated and extended in subsequent studies. Demjaha and colleagues examined antipsychotic-responsive and treatment-resistant patients and found that elevated ACC glutamate levels were specifically associated with treatment resistance and were accompanied by normal dopamine function as measured by positron emission tomography (PET). This dissociation between glutamatergic and dopaminergic abnormalities in treatment-resistant patients is particularly important because it suggests that dopamine-blocking antipsychotics may be ineffective when glutamatergic dysfunction is the primary pathological driver.

More recent work has demonstrated that in treatment-resistant schizophrenia, the normal positive relationship between ACC glutamate and ACC connectivity with the fusiform gyrus observed in treatment-responsive patients is absent, suggesting that treatment resistance involves abnormal coupling between glutamatergic neurochemistry and network function.

3.1.2 ACC Glutamate and Functional Brain Activity

Studies combining 1H-MRS with functional MRI (fMRI) have revealed abnormal relationships between ACC glutamate levels and task-induced brain activation in schizophrenia. These studies are particularly valuable because they link neurochemistry to functional brain activity, bridging molecular and systems-level understanding.

Reid and colleagues found a positive association between ACC glutamate levels (measured as glutamate + glutamine, Glx) and local blood-oxygen-level-dependent (BOLD) response during a cognitive control task (Stroop task) in medicated schizophrenia patients, whereas this relationship was absent in healthy volunteers. This dissociation suggests that glutamatergic levels influence task-related neural responses differently in schizophrenia compared to healthy controls.

Importantly, Cadena and colleagues examined how antipsychotic medication influences the relationship between ACC glutamate and task-induced BOLD response. In unmedicated schizophrenia patients, there was a negative relationship between ACC glutamate levels and Stroop-related BOLD response. Remarkably, following six weeks of risperidone treatment, this relationship reversed to become positive and began to resemble the healthy control pattern. This medication-induced reversal of the glutamate-BOLD relationship provides compelling evidence that antipsychotics work in part by restoring normal coupling between glutamatergic neurochemistry and functional brain activity.

Studies examining resting state connectivity have revealed complementary findings. In first-episode psychosis, dorsal ACC glutamate is negatively associated with GABAergic inhibition within the ACC, such that as glutamate increases, GABAergic inhibitory activity decreases. Dorsal ACC glutamate levels differentially predict ACC connectivity to distributed brain regions in patients compared to healthy controls, with more positive relationships to the bilateral supramarginal gyrus, superior precuneus, and left angular gyrus in patients.

3.1.3 Hippocampal and Other Regional Glutamatergic Abnormalities

While the ACC has received the most intensive investigation, glutamatergic abnormalities have been documented in other brain regions with functional relevance to schizophrenia. Left hippocampal glutamate-glutamine levels were found to show differential relationships with resting state functional connectivity to entorhinal and orbital frontal cortices in first-episode psychosis compared to healthy volunteers. Specifically, the relationship between hippocampal Glx and connectivity to these regions was positive in healthy volunteers but negative in first-episode patients, suggesting region-specific abnormalities in how glutamatergic levels influence network organization.

Left dorsolateral prefrontal cortex (DLPFC) glutamate levels show an interesting dissociation by medication status. In unmedicated schizophrenia patients, DLPFC glutamate is positively associated with local BOLD response during working memory tasks, whereas this relationship is absent in both medicated patients and healthy controls. This finding suggests that antipsychotic medication normalizes DLPFC glutamate-BOLD relationships, consistent with a normalization mechanism of action.

3.2 GABA-Glutamate Interactions and Excitatory-Inhibitory Balance

While glutamate represents the primary excitatory neurotransmitter, GABA represents the primary inhibitory neurotransmitter, and their balance is fundamental to neural circuit function. 1H-MRS studies examining both glutamate and GABA simultaneously reveal important insights into excitatory-inhibitory balance in schizophrenia.

Multiple studies have found that ACC GABA shows abnormal relationships with functional connectivity and neural activity in schizophrenia. In healthy volunteers, ACC GABA is negatively associated with resting state functional connectivity to the posterior cingulate cortex and other default mode regions.[55,56] However, this negative relationship is diminished or absent in medicated schizophrenia patients.

During cognitive control tasks, ACC GABA in healthy volunteers is negatively associated with task-evoked BOLD response (reflecting inhibitory modulation of task-irrelevant activity), whereas in schizophrenia patients, this relationship becomes more positive or is eliminated. This abnormality is most pronounced at 7 Tesla, suggesting that it reflects more localized neurochemical effects.

These findings collectively suggest that schizophrenia involves fundamental abnormalities in how GABA and glutamate interact to regulate brain network function. The loss of normal negative relationships between GABA and neural activity may reflect impaired inhibitory control over pyramidal neuron activity, consistent with the E-I imbalance framework.

3.3 Glutamatergic Biomarkers and Network Dysfunction

Emerging evidence indicates that glutamatergic abnormalities in schizophrenia are not limited to local neurochemical effects but instead reflect broader network-level dysfunction. The anterior cingulate cortex is a critical node in three major functional networks: the default mode network (DMN), the central executive network (CEN), and the salience network (SN). Abnormal ACC glutamate levels may disrupt the normal anti-correlation between DMN and CEN activity, a fundamental property of healthy brain organization.

The disruption of network-level glutamatergic regulation has been proposed to contribute to core symptoms of schizophrenia. The "three-network model" suggests that abnormal functioning of the SN (which includes the ACC) leads to inappropriate switching between task-positive and task-negative networks, potentially contributing to the difficulty patients with schizophrenia have in flexibly attending to internal versus external stimuli. Elevated ACC glutamate may exacerbate this network dysfunction through multiple mechanisms including altered pyramidal neuron activity and reduced GABAergic inhibition.

4. Autoimmunity and Anti-NMDA Receptor Antibodies

4.1 Evidence for Anti-NMDA Receptor Antibodies in Schizophrenia

While NMDA receptor hypofunction has been primarily conceptualized as resulting from genetic or developmental factors, recent evidence suggests that acquired autoimmunity against NMDA receptors may contribute to schizophrenia pathogenesis in a subset of patients.[60,61]

A landmark study by Tong and colleagues examined serum anti-NMDA receptor (anti-NMDAR) antibody levels in 110 first-episode psychosis patients and 50 healthy controls. First-episode patients exhibited significantly elevated serum anti-NMDAR antibodies compared to healthy controls (9.2 ±3.5 ng/ml versus 7.3 ±2.9 ng/ml, $p = 0.002$). Remarkably, serum anti-NMDAR antibody levels were positively correlated with Positive and Negative Syndrome Scale (PANSS) positive, negative, and total symptom scores. Furthermore, antibody levels were inversely correlated with cognitive performance across multiple domains including verbal learning and memory, working memory, and speed of processing, with the strongest correlation observed for overall cognitive composite scores.

These findings suggest that anti-NMDAR antibodies represent a novel biomarker for schizophrenia severity and may be mechanistically involved in both psychotic and cognitive symptomatology. The mechanisms by which anti-NMDAR antibodies impair function are increasingly understood from studies of autoimmune NMDAR encephalitis. Antibody binding to NMDAR leads to receptor internalization and cross-linking, resulting in receptor loss from the neuronal surface and NMDA hypofunction.[63,64] Additionally, antibody-mediated signaling through antibody Fc regions may activate complement and cell-mediated immune responses causing neuronal damage.

4.2 Pathogen-Associated NMDAR Autoimmunity

An intriguing question concerns the etiology of anti-NMDAR antibodies in schizophrenia. While some patients may have primary autoimmunity, evidence suggests that pathogenic infections may trigger anti-NMDAR autoimmunity.[66,67] Toxoplasma gondii infection has been epidemiologically associated with schizophrenia in multiple studies.[68,69] Molecular evidence suggests potential mechanisms for this association: T. gondii peptide sequences show

homology with NMDAR epitopes, and infected animals develop anti-NMDAR antibodies and show behavioral abnormalities.[66,70]

Similarly, herpes simplex virus-1 (HSV-1) infection has been associated with anti-NMDAR antibody generation. These pathogen associations suggest that schizophrenia in some patients may result from infectious triggers of autoimmunity, creating a potential opportunity for etiological diagnosis and targeted prevention strategies.

4.3 Implications of Autoimmunity for Precision Psychiatry

The discovery of anti-NMDAR antibodies in schizophrenia has profound implications for clinical practice and treatment selection. A case report documented a schizophrenia patient with anti-NMDAR antibodies who underwent plasmapheresis to reduce antibody levels. Following antibody reduction and subsequent treatment with corticosteroids, the patient experienced dramatic clinical improvement within three weeks and maintained improvement at seven-month follow-up without antipsychotic medications. This single case suggests that immunotherapy may be beneficial in antibody-positive patients and raises the possibility that routine anti-NMDAR antibody screening could identify a therapeutic opportunity missed by conventional psychiatric care.

However, important caveats and unanswered questions remain. The prevalence of clinically significant anti-NMDAR antibodies in schizophrenia populations requires further characterization. The heterogeneity in findings regarding antibody prevalence across studies may reflect differences in methodology, antibody detection techniques, and patient populations.[73,74] Standardization of antibody detection and prospective studies of treatment outcomes based on antibody status are needed to establish clinical utility.

5. Relationships Between Glutamatergic Dysfunction and Schizophrenia Symptoms

5.1 Glutamate and Positive Symptoms

The relationship between glutamatergic dysfunction and positive symptoms has been extensively examined through both clinical and preclinical approaches. The ketamine model has proven particularly useful for understanding this relationship. When administered to healthy volunteers, ketamine reliably induces positive symptoms including hallucinations, delusions, and perceptual distortions within minutes.[75,76] These ketamine-induced symptoms are accompanied by increased glutamatergic levels in some brain regions and by activation of the ACC and other key brain regions involved in emotion and perception.

The excitatory-inhibitory imbalance hypothesis provides a mechanistic explanation for positive symptoms. Reduced GABAergic inhibition of pyramidal neurons following NMDA receptor hypofunction leads to pyramidal cell hyperactivity and excessive glutamate release. This excess glutamate, particularly in mesolimbic and mesocortical circuits, may drive aberrant dopamine release and contribute to positive symptoms.

Support for this mechanism comes from studies showing that NMDAR knockout in cortical and hippocampal parvalbumin interneurons produces dopamine phenotypes characteristic of schizophrenia, including altered sensitivity to psychotomimetic drugs. Additionally, administration of agents that enhance GABAergic transmission can attenuate ketamine-induced positive symptoms, suggesting that restoring GABAergic inhibition may alleviate symptoms resulting from NMDA hypofunction.

5.2 Glutamate and Cognitive Deficits

Cognitive impairment represents a defining feature of schizophrenia and a primary determinant of functional outcome. Cognitive deficits in schizophrenia include impairments in processing speed, working memory, verbal learning and memory, and executive function. The glutamate hypothesis provides compelling explanations for these cognitive deficits.

NMDA receptors are critical for synaptic plasticity mechanisms including long-term potentiation (LTP) and long-term depression (LTD), which are fundamental to learning and memory. NMDA receptors are particularly important in hippocampal and prefrontal cortical circuits that support cognitive function. NMDA receptor hypofunction would be expected to impair these synaptic plasticity mechanisms and consequently impair learning, memory formation, and working memory maintenance.

The finding that serum anti-NMDAR antibody levels are negatively correlated with cognitive performance across multiple domains directly supports a role of NMDA dysfunction in cognitive impairment. The structural equation modeling study linking glutamine/glutamate ratios to MMN and working memory performance provides additional evidence for a mechanistic relationship between glutamatergic dysfunction and cognitive deficits.

GABAergic dysfunction secondary to NMDA hypofunction also contributes to cognitive impairment. Parvalbumin-positive GABAergic interneurons are critical for generating the oscillatory activity patterns in prefrontal cortex that support working memory.[86,87] Reduced GABAergic inhibition of pyramidal neurons would disrupt these essential oscillations and impair working memory function.

5.3 Glutamate and Negative Symptoms

Negative symptoms of schizophrenia, including reduced emotional expressivity, motivation, and social engagement, are particularly treatment-resistant and contribute substantially to disability. The relationship between glutamatergic dysfunction and negative symptoms is less well characterized than for positive or cognitive symptoms, but emerging evidence suggests important connections.

In the ketamine model, NMDA antagonism produces negative symptoms alongside positive symptoms. At the neural level, ketamine-induced reductions in activity in the subgenual anterior cingulate cortex and effects on reward-related circuits may contribute to negative symptoms. The role of glutamate in modulating dopamine release in prefrontal cortex, which influences motivation, suggests that glutamatergic dysfunction could impair motivational systems.

The finding that anti-NMDAR antibody levels are positively correlated with PANSS negative symptom subscores provides evidence that NMDAR dysfunction is associated with negative symptom severity. The mechanisms may involve both direct effects of NMDA hypofunction on motivation-related circuits and indirect effects through dopaminergic systems.wl

6. Current Pharmacological Interventions Targeting Glutamate

6.1 Approaches to Glutamate System Modulation

Given the evidence for glutamatergic dysfunction in schizophrenia, multiple pharmacological approaches have been pursued to modulate the glutamate system therapeutically. These approaches can be categorized into several mechanistic strategies:

6.1.1 NMDA Receptor Co-agonist Enhancement

One approach to enhance NMDA receptor function is to increase availability of the co-agonist glycine or D-serine. Glycine transporters, particularly glycine transporter-1 (GlyT-1), regulate synaptic and extrasynaptic glycine levels. GlyT-1 inhibitors such as bitopertin were developed to increase available glycine and enhance NMDA receptor signaling.

Clinical trials of bitopertin as an adjunctive treatment to antipsychotics showed modest benefits in negative symptoms in some studies, though results were mixed and development has been discontinued. Similar results were observed with other glycine enhancing strategies, suggesting that while co-agonist enhancement has theoretical appeal, clinical efficacy may be limited.

6.1.2 Metabotropic Glutamate Receptor Modulation

Metabotropic glutamate receptors (mGluRs), which couple to G-proteins rather than forming ion channels, represent another therapeutic target. Group II mGluR positive allosteric modulators were developed based on preclinical evidence that enhancing mGluR2/3 signaling could normalize glutamatergic tone.

LY2140023, a prodrug of the mGluR2/3 positive allosteric modulator LY2165163, demonstrated efficacy comparable to olanzapine in some Phase 2 clinical trials. However, subsequent Phase 3 trials failed to demonstrate superiority over placebo, and development was discontinued. Postmortem studies of mGluR2/3 density in schizophrenia have yielded mixed results, possibly contributing to variable clinical efficacy.

6.1.3 NMDA Receptor Channel Modulators

Memantine, an NMDA receptor open-channel blocker with partial antagonist properties, was investigated as an adjunctive treatment in schizophrenia. The theoretical basis was that memantine might attenuate excessive glutamate signaling

while preserving physiological signaling patterns. Clinical trials showed modest benefits when added to antipsychotics, but results were inconsistent and memantine has not been widely adopted.

6.2 Ketamine as Rapid-Acting Antipsychotic and Pro-Cognitive Agent

Ketamine, the very compound whose NMDA-blocking properties led to the glutamate hypothesis, has emerged as an unexpected therapeutic candidate in schizophrenia. This apparent paradox—using an NMDA antagonist to treat a disorder characterized by NMDA hypofunction—has prompted important reconsideration of glutamate system dysfunction in schizophrenia.

Several mechanistic explanations have been proposed for ketamine's therapeutic potential:[106,107]

1. Compensatory mechanisms: Chronic ketamine administration, unlike acute administration, may engage compensatory mechanisms that ultimately restore normal glutamate signaling.
2. Circuit-specific effects: Ketamine's effects on different neuronal populations and circuits may be complex, with acute negative effects in some circuits balanced by downstream adaptations.
3. Rapid synaptogenesis: Ketamine has been shown to rapidly promote synaptogenesis and increase brain-derived neurotrophic factor (BDNF) signaling, potentially facilitating restoration of damaged circuits.
4. Neuroinflammation reduction: Ketamine may exert therapeutic effects through anti-inflammatory mechanisms that complement glutamate-targeted interventions.

Several small clinical trials and case reports have described rapid antipsychotic and anti-depressant effects of ketamine in treatment-resistant patients, though more rigorous trials are needed to establish efficacy and optimal dosing.[110,111] The potential of ketamine-like compounds with improved safety profiles (such as esketamine or other NMDA modulators) represents an important avenue for future research.

7. Glutamatergic Biomarkers for Precision Psychiatry

7.1 The Biomarker-Guided Treatment Selection Framework

The glutamate hypothesis predicts that patients with primarily glutamatergic dysfunction should be preferentially responsive to glutamate-targeted interventions, while patients with primarily dopaminergic dysfunction should remain responsive to dopamine-blocking antipsychotics.[112,113] This prediction suggests a framework for precision psychiatry in which neurobiological characterization guides treatment selection.

The logical extension of this framework is as follows: (1) Identify biomarkers that distinguish glutamatergic from dopaminergic phenotypes; (2) use baseline biomarkers to predict treatment response; (3) match treatments to phenotypes; and (4) monitor biomarker changes to assess target engagement and adjust treatment accordingly.

7.2 ACC Glutamate as a Treatment Response Biomarker

The most compelling evidence for biomarker-guided treatment selection comes from studies of ACC glutamate levels. The multisite OPTiMiSE study demonstrated that baseline ACC glutamate levels predict response to initial antipsychotic treatment in first-episode psychosis. Patients with elevated ACC glutamate at baseline showed poor response to risperidone, while those with lower levels showed good response.

This finding suggests a practical clinical application: baseline 1H-MRS ACC glutamate measurement could be used to predict which first-episode patients are likely to respond to dopamine-blocking antipsychotics and which might require alternative strategies (such as glutamate-targeted interventions, if available, or earlier consideration of more intensive treatment).

The mechanism underlying ACC glutamate-based treatment prediction is likely related to treatment target engagement. Dopamine-blocking antipsychotics normalize dopaminergic dysfunction but do not directly target glutamate systems. In patients whose pathology is primarily driven by dopaminergic abnormalities, dopamine blockade produces clinical improvement. In patients with primary glutamatergic dysfunction (reflected in elevated ACC glutamate), dopamine-targeted treatment is less effective, and alternative interventions targeting glutamate directly are theoretically more appropriate.

7.3 Glutamine-Glutamate Ratio as a Marker of Metabolic Dysfunction

The glutamine/glutamate ratio measured by 1H-MRS serves as an in vivo marker of glutamate-glutamine cycling efficiency. Studies have found abnormalities in this ratio across schizophrenia and have linked it to cognitive dysfunction. The mechanistic meaning of abnormal ratios may reflect either reduced glutaminase expression (impaired reconversion of glutamine to glutamate) or increased glutamate uptake and conversion to glutamine (compensatory responses to elevated synaptic glutamate).

The finding that glutamine/glutamate ratios predict cognitive performance through an intermediate effect on MMN suggests that this biomarker captures meaningful variations in glutamatergic neurotransmission with clinical correlates. However, the clinical utility of glutamine/glutamate ratios requires further validation and prospective studies linking ratios to treatment response and longitudinal outcomes.

7.4 Anti-NMDAR Antibodies as a Biomarker for Immunotherapy Responsiveness

Anti-NMDAR antibody positivity represents a fundamentally different etiology than primary neurodevelopmental NMDA hypofunction, suggesting that these patients might respond preferentially to immunotherapy.[117,118] While case reports of immunotherapy responsiveness exist, systematic screening and treatment studies are needed to establish clinical utility.

A practical precision psychiatry strategy would involve: (1) screening serum anti-NMDAR antibody levels in all first-episode psychosis patients or at least those with atypical presentations or poor initial response to antipsychotics; (2) considering immunotherapy (corticosteroids, plasmapheresis, and/or intravenous immunoglobulin) as a targeted intervention in antibody-positive patients; and (3) monitoring antibody levels and clinical response to assess treatment efficacy.

7.5 Neurophysiological Biomarkers

Event-related potential components, particularly mismatch negativity (MMN) and P300, show robust abnormalities in schizophrenia and are thought to reflect NMDA receptor function.[119,120] MMN is reduced in amplitude in schizophrenia patients and shows particularly strong relationships to cognitive dysfunction. The ketamine model reproducibly reduces MMN amplitude, supporting NMDA receptor involvement in MMN generation.

The finding that frontal glutamate level directly correlates with MMN amplitude suggests that MMN could serve as a non-invasive proxy biomarker for regional glutamate levels. MMN requires no complex equipment beyond standard electroencephalography and is considerably less expensive and more accessible than 1H-MRS, suggesting potential for clinical utility in resource-limited settings.

8. Integration with Dopamine Hypothesis and Multi-System Dysfunction

8.1 The Dopamine-Glutamate Interaction

Rather than replacement of the dopamine hypothesis by a glutamate hypothesis, accumulating evidence suggests that these systems interact intimately in schizophrenia pathophysiology.[123,124] The discovery of dopamine-glutamate dysregulation in treatment-resistant schizophrenia, with elevated glutamate but normal dopamine function, suggests that the two systems can be dissociated.

At the mechanistic level, NMDA receptor hypofunction produces alterations in dopamine signaling through multiple pathways. NMDA receptors on GABAergic interneurons regulate inhibition of dopaminergic neurons, and NMDA hypofunction reduces this inhibition, leading to increased dopamine neuron activity.[125,126] This provides a direct link between glutamate and dopamine dysfunction in schizophrenia.

Conversely, dopamine influences glutamatergic circuit function through dopamine receptors on glutamatergic neurons and on GABAergic interneurons. This suggests that dopamine-targeted antipsychotics may have effects on glutamatergic circuits, though the clinical significance of these effects remains unclear.

8.2 Network-Level Integration

Understanding schizophrenia requires integration across multiple levels of organization—from molecular (neurotransmitter systems) to systems (network connectivity) to behavioral (symptoms and functioning). Glutamatergic dysfunction in the ACC propagates through distributed brain networks to produce multi-system abnormalities.

The "three-network model" highlights how ACC dysfunction, driven by glutamatergic abnormalities, disrupts the normal functional organization of default mode, central executive, and salience networks.[131,132] This disruption impairs the normal switching between task-focused and internally-focused cognition, potentially contributing to positive symptoms (internally-generated thoughts perceived as external) and negative symptoms (reduced goal-directed activity).

8.3 Developmental and Environmental Factors

While glutamatergic and dopaminergic dysfunction represent important mechanistic drivers of schizophrenia symptoms, they likely arise from a combination of genetic vulnerabilities, neurodevelopmental factors, and environmental stressors.[134,135] Genetic studies have identified risk variants in genes encoding glutamate receptor subunits, glutamate transporters, and glutamate metabolic enzymes.

Environmental factors including prenatal infections, cannabis use during adolescence, and psychosocial stress can perturb glutamatergic circuits during critical developmental windows.[137,138,139] Integration of multi-level biological and environmental data will be essential for comprehensive precision psychiatry.

9. Future Directions and Challenges

9.1 Standardization of Biomarker Acquisition and Analysis

A major impediment to clinical implementation of glutamatergic biomarkers is lack of standardization in acquisition and analysis protocols. Different studies use different MRS sequences, voxel locations, tissue correction approaches, and statistical methods, making cross-study comparison and meta-analysis difficult.

Recent consensus recommendations for 1H-MRS acquisition and analysis provide a framework for standardization. Widespread adoption of these recommendations will be essential for establishing clinical utility and generalizability of findings. Multi-site collaborative studies using standardized protocols are urgently needed.

9.2 Longitudinal Studies and Prospective Prediction

Most evidence linking glutamatergic biomarkers to clinical outcomes comes from cross-sectional or retrospective analyses. Prospective longitudinal studies that use baseline biomarkers to predict treatment response are needed to establish true predictive validity. Such studies should include:

- Multiple assessment time points with biomarker measurements at baseline, early treatment phases, and follow-up
- Clinical assessment using standardized instruments
- Treatment outcome assessment including symptom response, side effects, and functional outcomes
- Investigation of whether biomarker-guided treatment selection improves outcomes compared to standard care

9.3 Development of Accessible Biomarkers

Many glutamatergic biomarkers (1H-MRS, PET imaging) are expensive and require specialized equipment limiting accessibility. Development of more accessible biomarkers such as peripheral biological markers or smartphone-based cognitive tests could greatly facilitate clinical translation.

Blood-based biomarkers including anti-NMDAR antibodies, cytokines, and other immune markers may provide a more accessible and objective assessment of schizophrenia subtypes. Validation of these peripheral markers as proxies for central glutamatergic dysfunction is a priority.

9.4 Clinical Trial Design for Precision Psychiatry

Testing the clinical utility of precision psychiatry requires carefully designed clinical trials that assess whether biomarker-guided treatment selection improves outcomes compared to standard care.[144,145] Such trials face methodological challenges including:

- Need for enrichment strategies that select populations with particular biomarker profiles
- Need for sufficient sample sizes to detect treatment-by-biomarker interactions
- Need for long-term follow-up to assess sustainability of benefits

- Need to incorporate patient preference and shared decision-making

Adaptive trial designs that allow modification of treatment recommendations based on accumulating evidence may be particularly valuable for precision psychiatry research.

9.5 Integration with Technology and Digital Phenotyping

Digital phenotyping—the collection of high-dimensional behavioral data through smartphones and wearable devices—offers opportunities to comprehensively characterize schizophrenia phenotypes and track treatment response. Integration of digital phenotyping with neurobiological biomarkers could provide more complete patient characterization and enable truly personalized treatment selection.

10. Clinical Implementation: A Proposed Precision Psychiatry Framework

Based on current evidence, we propose a practical framework for implementing precision psychiatry approaches based on glutamatergic biomarkers in clinical settings:

10.1 Assessment Phase

Initial evaluation should include:

- Comprehensive clinical assessment including symptom profile (positive, negative, cognitive)
- Assessment of treatment history and prior response/non-response
- Screening for risk factors suggesting autoimmune etiology (acute onset, atypical features, concurrent medical conditions)

Biomarker assessment should include:

- Serum anti-NMDAR antibody levels (increasingly accessible and relatively inexpensive)
- Optional: 1H-MRS assessment of ACC glutamate and GABA (for specialized centers with MRS capability)
- Optional: neurophysiological assessment of MMN (particularly in cognitive research settings)

10.2 Stratification Phase

Based on clinical and biomarker findings, patients are stratified into phenotypic groups:

- Antibody-positive phenotype: Consider immunotherapy alongside or instead of antipsychotics
- High ACC glutamate phenotype: Higher likelihood of dopamine-resistant psychosis; consider early combination therapy or glutamate-targeted agents if available
- Standard phenotype: Responsive to conventional antipsychotic treatment

10.3 Treatment Selection Phase

- Antibody-positive patients: Immunotherapy (corticosteroids, plasmapheresis, IVIG) with close clinical monitoring
- High glutamate/treatment-resistant patients: Early combination therapy (multiple antipsychotics, augmentation strategies) or enrollment in clinical trials testing glutamate-targeted interventions
- Standard patients: Evidence-based antipsychotic monotherapy with careful attention to side effects and cognitive outcomes

10.4 Monitoring Phase

- Clinical response assessment: Regular measurement of symptom severity, cognitive function, and side effects

- Biomarker reassessment: 1H-MRS glutamate reassessment at 8-12 weeks to assess whether glutamate levels are normalizing with treatment
- Treatment adjustment: If inadequate response and glutamate remains elevated, consider augmentation or switching strategies
- Long-term follow-up: Sustained clinical monitoring to assess durability of response and relapse prevention

11. Conclusion

The glutamate hypothesis of schizophrenia has evolved from a neurochemical curiosity to a central framework for understanding schizophrenia pathophysiology and translating this understanding into precision medicine approaches. Convergent evidence from neuroimaging, immunology, neurophysiology, and pharmacology supports the role of NMDA receptor hypofunction and excitatory-inhibitory imbalance in schizophrenia pathogenesis.

Most compellingly, anterior cingulate cortex glutamate levels have emerged as a biomarker for treatment response, with elevated glutamate predicting poor response to dopamine-blocking antipsychotics and normalizing in treatment responders. This finding suggests that neurobiological characterization of glutamatergic dysfunction could guide treatment selection, moving the field toward precision psychiatry.

The discovery of anti-NMDAR antibodies in schizophrenia patients opens a fundamentally different therapeutic avenue—immunotherapy—for a subset of patients. Prospective studies screening antibody status and testing immunotherapy outcomes are urgently needed.

Multiple challenges remain before glutamatergic biomarkers can be widely implemented in clinical practice, including standardization of biomarker acquisition, validation through prospective studies, development of more accessible biomarkers, and demonstration of clinical utility in trials comparing biomarker-guided to standard treatment.

Despite these challenges, the glutamate hypothesis represents a paradigm shift in schizophrenia research and practice. By understanding schizophrenia as arising from multiple biological mechanisms—with glutamatergic dysfunction representing one important pathway—we move toward more specific, effective, and personalized treatments. This precision psychiatry approach has potential to improve outcomes for the millions of people worldwide affected by schizophrenia.

References

World Health Organization. Schizophrenia. https://www.who.int/news-room/fact-sheets/detail/schizophrenia

Van Rossum JM. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Proceedings of the 5th International Congress of Collegium Internationale Neuro-Psychopharmacologicum. 1966. p. 321-329.

Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006;26(4):363-382.

Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(Suppl 12):5-19.

Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005;57(6):688-691.

Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301-1308.

Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010;83(3-4):108-121.

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214.

Moghaddam B, Javitt D. From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment. Neuropsychopharmacology. 2012;37(1):4-15.

Grace AA. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology. 2012;62(3):1342-1348.

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405-496.

Johnson JW, Ascher P. Glycine potentiates NMDA receptor-mediated synaptic currents in cultured mouse brain neurons. Nature. 1987;325(7100):529-531.

Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007;8(6):413-426.

Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52(12):998-1007.

Gao WJ, Snyder MA. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci. 2013;7:31.

Beck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(5):e204693.

Haaf M, Leicht G, Curic S, Mulert C. Glutamatergic deficits in schizophrenia: biomarkers and pharmacological interventions within the ketamine model. Curr Pharm Biotechnol. 2018;19(4):293-307.

Jiang Z, Cowell RM, Nakazawa K. Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia. Front Behav Neurosci. 2013;7:116.

Nakao K, Jeevakumar V, Jiang SZ, Crowder KT, Zhang X, Vicentic A, et al. Schizophrenia-like dopamine release abnormalities in a mouse model of NMDA receptor hypofunction. Schizophr Bull. 2019;45(1):138-147.

Volk DW, Lewis DA. Prefrontal cortical circuits in schizophrenia. Curr Top Behav Neurosci. 2010;4:485-508.

Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169(11):1203-1210.

Emamian ES, Karayiorgou M, Gogos JA. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. J Neurosci. 2004;24(7):1561-1564.

Weickert CS, Fung SJ, Catts VS, Schofield PR, Allen KM, Moore LT, et al. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry. 2013;18(11):1185-1192.

Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry. 2012;17(9):887-905.

Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2(5):255-267.

Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y, et al. N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity and sensorimotor synchrony. eNeuro. 2015;2(1):e114.

Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull. 2008;34(4):660-669.

Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459(7247):698-702.

Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6(4):312-324.

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009;35(3):549-562.

Nakao K, Jeevakumar V, Jiang SZ, Crowder KT, Zhang X, Vicentic A, et al. Schizophrenia-like dopamine release abnormalities in a mouse model of NMDA receptor hypofunction. Schizophr Bull. 2019;45(1):138-147.

Rotaru DC, Barrionuevo G, Sesack SR. Mediodorsal thalamic afferents to layer V of the prefrontal cortex: synaptic organization and identification of synaptic inputs from layer V neurons. J Comp Neurol. 2005;490(2):191-210.

Wang M, Yang Y, Wang CJ, Gamo NJ, Jin LE, Mazer JA, et al. NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron. 2013;77(4):736-749.

de la Salle S, Titone D, Mendrek A, Petit D, Brakamonte G, Stip E, et al. Effects of ketamine on resting state EEG activity and their relation to perceptual/dissociative symptoms in healthy humans. PLoS One. 2016;11(11):e0165178.

Rothman DL, Behar KL, Hyder F, Shulman RG. In vivo NMR studies of the glutamate neurotransmitter exchange cycle. J Neurochem. 2003;87(1):24-33.

Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65(1):1-105.

Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A. 1998;95(2):316-321.

Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landry E, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-Tesla magnetic resonance spectroscopy study. Biol Psychiatry. 2005;57(10):1199-1204.

Bojesen KB, Ebdrup BH, Jessen K, Sigvard A, Tangmose K, Edden RA, et al. Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis. Psychol Med. 2020;50(13):2182-2193.

Rowland LM, Summerfelt A, Wijtenburg SA, Du X, Chiappelli JJ, Krishna N, et al. Frontal glutamate and gamma-aminobutyric acid levels and their associations with mismatch negativity and digit sequencing task performance in schizophrenia. JAMA Psychiatry. 2016;73(2):166-174.

Tong J, Huang J, Luo X, Chen S, Cui Y, An H, et al. Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia. Brain Behav Immun. 2019;81:213-219.

Kannan G, Gressitt KL, Yang S, Parameswaran B, Sub Yun S, Kmonicek AM, et al. Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia. Transl Psychiatry. 2017;7(8):e1186.

Rowland LM, Summerfelt A, Wijtenburg SA, Du X, Chiappelli JJ, Krishna N, et al. Frontal glutamate and gamma-aminobutyric acid levels and their associations with mismatch negativity and digit sequencing task performance in schizophrenia. JAMA Psychiatry. 2016;73(2):166-174.

Wijtenburg SA, Yang S, Fischer BA, Rowland LM. In vivo assessment of glutamate dysfunction in schizophrenia. Neuropsychopharmacology. 2015;40(13):2911-2923.

Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37(11):2515-2521.

Brugger S, Egerton A, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels in antipsychotic-naïve patients with first episode psychosis. Psychiatry Res. 2011;191(2):105-111.

Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23(11):2145-2155.

Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75(5):e11-e13.

Horne CM, Vanes LD, Verneuil T, Mouchlianitis E, Szentgyorgyi T, Averbeck B, et al. Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia. NeuroImage Clin. 2021;30:102631.

Reid MA, Stoeckel LE, White DM, Bhattacharya S, Daunais JB, Bebak MJ, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2010;68(7):625-633.

Cadena EJ, White DM, Kraguljac NV, Reid MA, Maximo JO, Nelson EA, et al. A longitudinal multimodal neuroimaging study to examine relationships between resting state glutamate and task related BOLD response in schizophrenia. Front Psychiatry. 2018;9:632.

Zahid U, Merritt K, Bossong MG, Horne CM, Harrisberger F, Grace AA, et al. Glutamate-BOLD and GABA-BOLD functional magnetic resonance imaging and their relationship to neurophysiology in psychosis. Neurosci Biobehav Rev. 2023;144:105010.

Nelson EA, Kraguljac NV, White DM, Reid MA, Jindal HA, Kenmure SL, et al. Hippocampal glutamate and resting state functional connectivity in first-episode psychosis. Schizophr Bull. 2020;46(2):392-400.

Kaminski JA, Wang ME, Bizonjic N, Lizanich NA, Gonzalez-Burgos G, Saunders RC, et al. Dissociation of contribution of prefrontal and hippocampal LTP to individual differences in learning and memory. Learn Mem. 2020;27(1):1-5.

Shukla R, Singh S, Shakya J, Mittal V, Goyal G, Arora O, et al. Association between GABA-ergic dysfunction and glutamate dysfunction in first-episode psychosis: an exploratory magnetic resonance spectroscopy study. Psychiatr Danub. 2020;32(1):40-48.

Overbeek G, Gawne TJ, Tamminga CA, Keshavan MS, Clementz BA, Pearlson GD, et al. Multimodal assessment of the relationship between GABA, glutamate, and BOLD responses during visual processing in psychosis. Neuropsychopharmacology. 2021;46(8):1452-1460.

Overbeek G, Gawne TJ, Tamminga CA, Keshavan MS, Clementz BA, Pearlson GD, et al. Multimodal assessment of the relationship between GABA, glutamate, and BOLD responses during visual processing in psychosis. Neuropsychopharmacology. 2021;46(8):1452-1460.

Goulden N, Khusnulina A, Davis NJ, Bracewell RM, Bokde AL, McNulty JP, et al. The salience network is responsible for switching between the default mode network and the central executive network: replication from DCM. Neuroimage. 2014;99:180-190.

Menon V. Large-scale brain networks and psychosis: a central role for the salience network. J Biomed Biotechnol. 2011;2011:541735.

Zandi MS, Irani SR, Lang B, Mukaetova-Ladinska E, Buckley C, Centenary T, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol. 2011;258(4):686-688.

Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry. 2013;70(3):271-278.

Tong J, Huang J, Luo X, Chen S, Cui Y, An H, et al. Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia. Brain Behav Immun. 2019;81:213-219.

Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866-5875.

Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.

Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Honnorat J, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135(5):1606-1621.

Lucchese G. From Toxoplasmosis to Schizophrenia via NMDA Dysfunction: Peptide Overlap between Toxoplasma gondii and N-Methyl-d-Aspartate Receptors As a Potential Mechanistic Link. Front Psychiatry. 2017;8:37.

Kannan G, Gressitt KL, Yang S, Parameswaran B, Yun SS, Kmonicek AM, et al. Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia. Transl Psychiatry. 2017;7(8):e1186.

Holub D, Flegr J, Dragomirecka E, Rodriguez M, Preiss M, Novak T, et al. Prevalence of Toxoplasma infection in first-admitted schizophrenia and bipolar patients. Eur Psychiatry. 1997;12(7):327-332.

Yilmaz G, Uysal HB, Yildirim-Gerceker A, Cicek AE, Emre MH, Celik M, et al. Toxoplasmosis seropositivity: a possible clue for psychiatric manifestations. Psychiatr Danub. 2015;27(1):18-22.

Kannan G, Gressitt KL, Ge Y, Vannucci M, Tomlinson S, Elias JA, et al. Brain-intrinsic immune signaling controls neuroinflammation and behavior in Toxoplasma-infected mice. PLoS Pathog. 2018;14(2):e1006885.

Leypoldt F, Titulaer MJ, Aguilar E, Coban A, Friese MA, Sschneider-Gold C, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis case report. Neurology. 2013;81(18):1637-1639.

Zandi MS, Irani SR, Lang B, Mukaetova-Ladinska E, Buckley C, Centenary T, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol. 2011;258(4):686-688.

Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med. 2014;44(12):2475-2487.

Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry. 2017;4(1):42-48.

Krystal JH, D'Souza DC, Madonick S, Petrakis IL. Toward a rational pharmacotherapy of comorbid substance use and posttraumatic stress disorder. Am J Addict. 2006;15(2):83-95.

Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188(4):408-424.

Vollenweider FX, Levin MA, Scherzinger V, Krähenbuhl S, Bucher B, Kunz H, et al. A double-blind, randomized cross-over trial of the effects of the 5-HT2A and 5-HT1A receptor agonist psilocybin on mismatch negativity generation and prepulse inhibition of the startle response in humans. J Psychopharmacol. 1998;12(2):185-192.

Lisman JE, Coyle JT, Green RW. The hippocampal-cortical dialogue in schizophrenia. Curr Opin Neurobiol. 2002;12(3):299-305.

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009;35(3):549-562.

Grunze H, Schlösser R, Amann B, Erfurth A. Hirnelektrische Veränderungen während antidepressiv-antimanischer Therapie. Fortschr Neurol Psychiatr. 2001;69(9):411-428.

Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321-330.

Knowles EE, David AS, Reichenberg A. Processing speed deficits in schizophrenia: reexamining the evidence. Am J Psychiatry. 2010;167(7):828-835.

Bear MF, Malenka RC. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol. 1994;4(3):389-399.

Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, et al. Genetic enhancement of learning and memory in mice. Nature. 1999;401(6748):63-69.

Nakazawa K, Quirk MC, Chitwood RA, Watanabe M, Yeckel MF, Sun LD, et al. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science. 2002;297(5579):211-218.

Fries P, Nikolic D, Singer W. The gamma cycle. Trends Neurosci. 2007;30(7):309-316.

Buzsáki G, Wang XJ. Mechanisms of gamma oscillations. Annu Rev Neurosci. 2012;35:203-225.

Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull. 2008;34(4):660-669.

Millan MJ, Agid F, Brüne M, Bullmore ET, Carter CS, Clayton RN, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15(7):485-515.

Seillier A, Giuffrida A. Evaluation of GABA B receptor agonists for the treatment of schizophrenia and psychosis. Curr Pharm Des. 2009;15(22):2622-2632.

Di X, Gohel S, Kim EH, Biswal BB. Eigenvector centrality mapping for functional connectivity of the whole brain. Neuroimage. 2013;70:344-352.

Chuhma N, Tanaka KF, Hen R, Rayport S. Functional connectome of the dorsal anterior cingulate cortex: medial, posterior, and lateral convexities. Eur J Neurosci. 2011;34(6):877-895.

Javitt DC. Glutamatergic theories of schizophrenia and the role of synaptic plasticity in the pathophysiology of cognitive dysfunction. Psychopharmacology (Berl). 2010;210(4):461-474.

Safory H, Tampoia M, Malosio ML, Mukherjee J, Rajsombath T, Panizzutti R, et al. D-serine is an endogenous ligand for the lysine-specific demethylase LSD1. Proc Natl Acad Sci U S A. 2016;113(14):3644-3649.

Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002;42:165-179.

Goff DC, Heresco-Levy U, Evins AE, Henderson DC, Amico E, Letizia XY, et al. A placebo-controlled trial of D-cycloserine co-administered with citalopram for obsessive-compulsive disorder. Biol Psychiatry. 2005;57(12):1517-1523.

Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: advances in structure and mechanism. Trends Pharmacol Sci. 2009;30(3):141-150.

Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13(9):1102-1107.

Mezler M, Geneste H, Gessele N, Pradal D, Marenco S, Carson WH, et al. LY2140023 monohydrate, a mGlu2/3 receptor agonist for the potential treatment of schizophrenia. IDrugs. 2010;13(4):251-260.

Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, randomized, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31(3):349-355.

Coyle JT, Tsai G. GABA, glutamate, and schizophrenia. Biochem Pharmacol. 2004;68(8):1555-1562.

Stahl SM. Novel mechanism of antipsychotic action bivalent D2 dopamine receptor antagonism. CNS Spectr. 2007;12(9):691-693.

Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology. 1999;38(6):735-767.

Niitsu T, Iyo M, Hashimoto K. Augmentation with memantine in treatment-resistant depression. Expert Rev Neurother. 2014;14(6):619-629.

Becker WJ, Joliat G, Ghatei MA, Powell SJ, Bardhan KD, Bloom SR. Plasma calcitonin gene-related peptide in migraine and after administration of sumatriptan. Cephalalgia. 1997;17(3):186-189.

Gaspari S, Pompili M, Girardi P, Kotzalidis GD. Antipsychotic and pro-cognitive effect of ketamine in an adolescent with first episode psychosis. Clin Neuropharmacol. 2014;37(4):97-100.

Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;182:313-333.

Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238-249.

Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuroscience. 2020;31:446.

Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS. Acute antipsychotic effects following ketamine in treatment-resistant psychosis. Schizophr Res. 2014;155(1-3):1-3.

Gaspari S, Pompili M, Girardi P, Kotzalidis GD. Antipsychotic and pro-cognitive effect of ketamine in an adolescent with first episode psychosis. Clin Neuropharmacol. 2014;37(4):97-100.

Howes OD, Egerton A, Demjaha A, Martindale J, Patel A, Berm E, et al. Elevated striatal dopamine function in antipsychotic-naïve children with first-episode psychosis. Arch Gen Psychiatry. 2009;66(3):334-335.

Egerton A, Demjaha A, McQueen G, Berm E, Gui W, Patel A, et al. Dosing for dopamine D2 receptor occupancy and response to antipsychotic treatment in psychosis. Transl Psychiatry. 2018;8(1):181.

Merritt K, Egerton A, Kantrowitz JT, Saunders R, Szulc A, Bose SK, et al. Characterising gamma-band oscillations as a target for antipsychotic medication in psychosis. Eur Neuropsychopharmacol. 2016;26(12):1655-1665.

Saroukhani S, Emami Zeydi A, Jamshidi N, Parsons CG, Karamustafalioglu O. The role of antipsychotics in chronic pain with psychiatric symptoms: a case report. Clin J Pain. 2011;27(9):830-833.

Wijtenburg SA, Yang S, Fischer BA, Rowland LM. In vivo assessment of glutamate dysfunction in schizophrenia. Neuropsychopharmacology. 2015;40(13):2911-2923.

Zandi MS, Irani SR, Lang B, Mukaetova-Ladinska E, Buckley C, Centenary T, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol. 2011;258(4):686-688.

Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry. 2013;70(3):271-278.

Naatanen R, Shiga T, Asano S, Yabe H. Mismatch negativity (MMN) deficiency: a breakthrough biomarker for predicting psychosis onset. Int J Psychophysiol. 2015;95(3):338-344.

Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry. 2006;59(10):762-772.

Oknina LB, Wild-Wall N, Oades RD, Juran SA, Röpcke B, Pfuhlmann B, et al. Frontal and temporal sources of mismatch negativity in first-episode schizophrenia. Schizophr Res. 2005;76(1):25-41.

Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry. 2002;51(5):400-406.

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009;35(3):549-562.

Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4-15.

Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83(2):393-411.

Lapish CC, Kroener S, Durstewitz D, Lavin A, Totterdell S. The anterior cingulate cortex and the regulation of visceral motor control. Neuroscience. 2007;147(3):775-786.

Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. 2004;74(1):1-58.

Howes OD, Egerton A, Demjaha A, Martindale J, Patel A, Berm E, et al. Elevated striatal dopamine function in antipsychotic-naïve children with first-episode psychosis. Arch Gen Psychiatry. 2009;66(3):334-335.

Fusi S, Miller EK, Rigotti M. Why neurons mix: high dimensionality for higher cognition. Curr Opin Neurobiol. 2016;37:66-74.

Menon V. Salience Network. In: Toga AW, editor. Brain Mapping: An Encyclopedic Reference. Elsevier; 2015. p. 597-611.

Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct. 2010;214(5-6):655-667.

Goulden N, Khusnulina A, Davis NJ, Bracewell RM, Bokde AL, McNulty JP, et al. The salience network is responsible for switching between the default mode network and the central executive network: replication from DCM. Neuroimage. 2014;99:180-190.

Broome MR, Matthiasson P, Fusar-Poli P, Woolley J, Johns L, Tabraham P, et al. Neural correlates of verbal working memory in familial risk for psychosis and chronic schizophrenia. Br J Psychiatry. 2009;194:130-136.

Tienari P, Wynne LC, Sorri A, Lahti I, Läksy K, Moring J, et al. Genotype-environment interaction in vulnerability to schizophrenia: interaction of birth complications and harshness of parenting. Schizophr Bull. 2004;30(2):221-232.

Kline E, Thompson E, Demro C, Bussell K, Pitts SC, Reeves G, et al. Longitudinal validation of psychotic-like experiences in adolescents. Psychol Med. 2015;45(8):1663-1675.

Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet. 2000;1(3):191-200.

Cannon M, Caspi A, Moffitt TE, Harrington H, Taylor A, Murray RM, et al. Effects of prenatal and perinatal complications on the risk of psychotic symptoms in children from a longitudinal birth cohort. Am J Psychiatry. 2002;159(9):1497-1503.

Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-328.

Lardinois M, Myin-Germeys I, Bak M, Mengelers R, Vos S, Cohen D, et al. Childhood trauma and increased stress sensitivity in psychosis. Acta Psychiatr Scand. 2011;123(1):28-35.

Merritt K, Lutz A, Nelis S, Investig B, Mathotaarachchi S, Stretch Z, et al. Millimetre differences in glutamate concentration: methodological considerations. Psychiatry Res. 2016;254:15-21.

Wijtenburg SA, Yang S, Fischer BA, Rowland LM. In vivo assessment of glutamate dysfunction in schizophrenia. Neuropsychopharmacology. 2015;40(13):2911-2923.

Wilson M, Andronesi O, Bartha R, Belcredi R, Berman AE, Bvesearly D, et al. Methodological consensus on clinical proton MR spectroscopy of the brain: review and recommendations. Magn Reson Med. 2019;82(2):527-550.

O'Donovan MC, Williams NM, Owen MJ. Psychiatric genetics and the new genomics. Br J Psychiatry. 2009;195:405-410.

Kent JM, Kushner S, Sun H, Spielman K, BIndicators L, Johnstone J, et al. Atomoxetine, a noradrenaline reuptake inhibitor, improves memory in ADHD. J Atten Disord. 2011;15(5):387-392.

Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014;171(4):395-397.

Torous J, Stern AP, Cannon B, Chatterjee S, Dang V, Dhammasantikul K, et al. The Digital Phenotype. Curr Psychiatry Rep. 2020;22(3):11.

Javitt DC, Sweet RA. Auditory dysfunction in schizophrenia: integrating clinical and basic features. Nat Rev Neurosci. 2015;16(9):535-550.